# BRUKINSA® (zanubrutinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zanubrutinib

> The FDA approved BRUKINSA® (zanubrutinib), sponsored by BeOne Medicines Ltd. (ONC), on June 10, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | BRUKINSA® (zanubrutinib) |
| Codes | BGB3111, BGB-3111 |
| Sponsor | BeOne Medicines Ltd. (ONC) https://sec-api.dev/companies/onc/catalysts |
| Indications | previously untreated mantle cell lymphoma, [B-cell Malignancies](https://sec-api.dev/indications/b-cell-malignancies), [Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://sec-api.dev/indications/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma), [Relapsed/Refractory Follicular Lymphoma](https://sec-api.dev/indications/relapsed-refractory-follicular-lymphoma), Mantle Cell Lymphoma; Non-Hodgkin Lymphoma, [Primary Membranous Nephropathy](https://sec-api.dev/indications/primary-membranous-nephropathy) |
| Modality | small_molecule |
| FDA designations | accelerated, priority review |

## Timeline

### November 14, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213217 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191114, review_priority PRIORITY; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22

### August 31, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213217 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20210831, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22

### September 14, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213217 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20210914, review_priority PRIORITY; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22

### January 19, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213217 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20230119, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22

### December 21, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213217 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20231221, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22

### March 7, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213217 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20240307, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22

### June 10, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-08-06, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218785 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250610, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218785%22
- openFDA Drugs@FDA: "NDA218785 ORIG-2 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250610, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218785%22
- SEC Form 10-Q (accession 0001651308-25-000133): "On June 11, 2025, we announced that the U.S. Food and Drug Administration approved a new tablet formulation of BRUKINSA for all five approved indications." https://www.sec.gov/Archives/edgar/data/1651308/000165130825000133/bgne-20250630.htm

### January 9, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04116437 (Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-09 (ACTUAL); Lead Sponsor BeiGene." https://clinicaltrials.gov/study/NCT04116437

### February 26, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-02-26, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-011941): "BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership" https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/exhibit991-q42025earningsr.htm

### April 27, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04002297 (A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-27 (ACTUAL); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT04002297

### June 30, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: previously untreated mantle cell lymphoma.
- First seen 2026-08-05, last confirmed 2026-08-05.
- SEC Form 10-Q (accession 0001628280-26-052878): "On June 30, 2026, we announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306) evaluating foundational Bruton's tyrosine kinase ("BTK") inhibitor BRUKINSA® plus rituximab versus bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma ("MCL")." https://www.sec.gov/Archives/edgar/data/1651308/000162828026052878/bgne-20260630.htm

### Dec 2026: interim data readout

- Status: scheduled. Date confidence: month.
- First seen 2026-11-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-127041): "To date, 12 patients have been enrolled in the study with initial data expected in December 2026." https://www.sec.gov/Archives/edgar/data/1108205/000110465926127041/tm2629651d1_ex99-1.htm

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: B-cell Malignancies.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04170283 (A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT04170283

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: B-cell Malignancies.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04170283 (A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT04170283

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Primary Membranous Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05707377 (A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT05707377

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Primary Membranous Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05707377 (A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT05707377

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05100862 (A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT05100862

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05100862 (A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor BeOne Medicines." https://clinicaltrials.gov/study/NCT05100862

## Same indication

- [ALXN1920](https://sec-api.dev/pdufa/alxn1920) (AZN)
- [Yescarta (axicabtagene ciloleucel)](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) (GILD)
- [Budoprutug](https://sec-api.dev/pdufa/budoprutug) (CLYM)
- [Povetacicept](https://sec-api.dev/pdufa/povetacicept) (VRTX)
- [Surovatamig](https://sec-api.dev/pdufa/surovatamig) (AZN)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zanubrutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BRUKINSA® (zanubrutinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zanubrutinib

```bibtex
@misc{secapidev_pdufa_zanubrutinib_20261116,
  title        = {BRUKINSA® (zanubrutinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zanubrutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zanubrutinib_20261116","title":"BRUKINSA® (zanubrutinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zanubrutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
